

Treatment of high risk testicular tumour with high dose chemotherapy with peripheral blood stem cells

Submission date 12/09/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 12/09/2003	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 20/04/2016	Condition category Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr PM Wilkinson

Contact details

Clinical Oncology
Christie Hospital NHS Trust
Wilmslow Road
Withington
Manchester
United Kingdom
M20 4BX
+44 0161 446 3261
Peter.Wilkinson@christie-tr.nwest.nhs.uk

Additional identifiers

Protocol serial number

N0063044257

Study information

Scientific Title

Treatment of high risk testicular tumour with high dose chemotherapy with peripheral blood stem cells

Study objectives

To assess the efficacy of high dose chemotherapy with peripheral blood stem cells to see if the response rate is improved compared to conventional therapy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Cancer: Testicular

Interventions

High dose chemotherapy with peripheral blood stem cells vs no high dose

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

1. Time to white cell and platelet recovery
2. Confirmation of response
3. Assessment of toxicity by standard World Health Organisation (WHO) grades

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/12/2008

Eligibility**Key inclusion criteria**

1. Patients with histological proven non-seminomatous germ cell tumours
2. High risk factors as defined by MRC prognostic group

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Male

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/05/1994

Date of final enrolment

31/12/2008

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Clinical Oncology

Manchester

United Kingdom

M20 4BX

Sponsor information**Organisation**

Department of Health (UK)

Funder(s)

Funder type

Government

Funder Name

Christie Hospital NHS Trust (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration